Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance FLT3 inhibitor therapy after umbilical cord blood transplantation in AML
jRCT1031230158Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in acute myeloid leukemia (AML), sponsored by Astellas Pharma. Primary endpoint: 1-year progression-free survival after UCBT. Started Jun 2023; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT1031230158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230158.